New Scientific Study Supports Combination Therapy for Effective Weight Management in Obesity Treatment Currax Pharmaceuticals brings attention to a new peer-reviewed study advocating for combination pharmacotherapy to improve management of obesity through targeted treatments.

New Scientific Study Supports Combination Therapy for Effective Weight Management in Obesity Treatment #United_States #Weight_Management #Brentwood #CONTRAVE #Currax_Pharmaceuticals

Currax Pharmaceuticals Enhances Access to Contrae with PeekDirect Technology Currax Pharmaceuticals partners with PeekDirect to expand availability of its obesity treatment Contrave. This model promotes price transparency and reduces patient costs.

Currax Pharmaceuticals Enhances Access to Contrae with PeekDirect Technology #USA #Brentwood #CONTRAVE #Currax_Pharmaceuticals #PeekDirect

Currax Pharmaceuticals Unveils Promising Data on CONTRAVE®'s Effectiveness During ObesityWeek® Currax Pharmaceuticals showcases promising data on CONTRAVE®'s ability to control cravings during ObesityWeek®, revealing significant outcomes for specific populations.

Currax Pharmaceuticals Unveils Promising Data on CONTRAVE®'s Effectiveness During ObesityWeek® #USA #Atlanta #CONTRAVE #Currax_Pharmaceuticals #ObesityWeek

Currax Pharmaceuticals to Showcase BREAKTHROUGH Research at ObesityWeek® 2025 on CONTRAVE® and Weight Management Currax Pharmaceuticals will present significant research on CONTRAVE® at ObesityWeek 2025, revealing its impact on craving control and weight management.

Currax Pharmaceuticals to Showcase BREAKTHROUGH Research at ObesityWeek® 2025 on CONTRAVE® and Weight Management #United_States #Atlanta #CONTRAVE #Currax_Pharmaceuticals #ObesityWeek

Currax Pharmaceuticals Offers CONTRAVE® Free for Federal Employees Amid Shutdown Crisis In response to the ongoing government shutdown, Currax Pharmaceuticals has announced it will provide its weight-loss medication, CONTRAVE®, at no cost to eligible federal employees and retirees.

Currax Pharmaceuticals Offers CONTRAVE® Free for Federal Employees Amid Shutdown Crisis #United_States #Brentwood #government_shutdown #CONTRAVE #Currax_Pharmaceuticals

Currax Pharmaceuticals Expands CONTRAVE Production with FDA Approval of New Facility Currax Pharmaceuticals has secured FDA approval for a second manufacturing site for their weight loss drug CONTRAVE, ensuring broader patient access and meeting the rising demand for obesity treatments.

Currax Pharmaceuticals Expands CONTRAVE Production with FDA Approval of New Facility #United_States #FDA_Approval #Brentwood #CONTRAVE #Currax_Pharmaceuticals

Currax Pharmaceuticals Achieves Remarkable Financial Growth and Operational Milestones for 2024 Currax Pharmaceuticals has reported exceptional results in 2024, including over 50% revenue growth, strategic operational advancements, and a global expansion in demand for its products.

Currax Pharmaceuticals Achieves Remarkable Financial Growth and Operational Milestones for 2024 #United_States #Brentwood #CONTRAVE #Currax_Pharmaceuticals #MYSIMBA